Business Wire
21 Sept 2026, 10:45 UTC · 2h ago
Verdict
Headline leans bullish. We score MRK +0.80 across one claim.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Japan's MHLW approved KEYTRUDA QLEX (KEYJECT) for subcutaneous administration across all current KEYTRUDA indications in Japan.
Newannouncement dated 2026-09-21
More positive than 76% of claims this week
Which stocks this story touches
Continue reading
5 related stories
More positive than 83% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 83% of ticker scores this week
The company received regulatory approval from Japan's MHLW for the subcutaneous version of its drug Keytruda.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
3d ago
Proactive Investors
1h ago
—
MRK hasn't traded since this ran. Last close $146.76 (Sep 18); the reaction starts at the next open.
MRK chart →
